

Curriculum Vitae

Personal information

First name(s) / Surname(s) **Giuseppe Paolisso**
Address(es) University of Campania, L. Vanvitelli, Dept of Advanced Medical and Surgical Sciences
Piazza Miraglia 2, 80138 Napoli
Telephone(s)
E-mail Giuseppe.paolisso@unicampania.it
Nationality Italian
Date of birth
Gender male

Work experience

2000-Present Full Professor of Internal Medicine and Geriatrics
Department of Medical, Surgical, Neurological, Metabolic and Geriatric Sciences, University
of Campania, Luigi Vanvitelli (Italy)
2014–2020 Chancellor of University of Campania, Luigi Vanvitelli (Italy)
University of Campania, Luigi Vanvitelli (Italy)
2015-2018 Member of National Committee for Food Security-
National Health Council for Italian Ministry, Rome (Italy)
2013-2014 Vice President III Section of National Health Council for Italian Minister.
National Health Council for Italian Ministry, Rome (Italy).
2001-Present Director of VI Division of Internal Medicine and Nutritional Diseases
University of Campania, Luigi Vanvitelli (Italy)
2010–2013 Member of Section of National Health Council for Italian Minister
National Health Council for Italian Ministry, Rome (Italy)
2013–2014 Coordinator of Medicine School
Second University of Naples, Naples (Italy)
2010–2012 Dean of School of Medicine of Second University of Naples
Second University of Naples, Caserta (Italy)
2006–2010 Director of the Pre- Medicine program of medical School
Second University of Naples, Naples (Italy)
2002–2014 Director of Geriatric Residency Program
Second University of Naples, Naples (Italy)

Education and training

1993-1994 Research Fellow-NIH
National Institute of Health-Clinical Diabetes and Nutrition Section Phoenix -AZ (USA).
1989 Specialist in Geriatric Medicine
University of Naples “Federico II”, Naples (Italy)
198 Specialist in Diabetes and Metabolic Disease
University of Naples “Federico II”, Naples (Italy)

1984-1985 /1986-1987	Research Fellow- University of Liege (BE). University of Liege (BE).
1983-1984	Research Fellow, Department of Physiology, Catholic University, Brussels (BE).
1981–Present	Medical Doctor (summa cum laude) University of Naples “Federico II”, Naples (Italy)

Personal skills and competences

Awards	<ul style="list-style-type: none"> – 2019 Honorary Degree "Administration of Innovation and Social Transformation" from the Pyatigorsk State University, Russia – 2017 Winner of the International award Sebetia – Ter (IT) – 2017 Winner of the award Euromediterraneo (Accademy Ercolanense).
Grants	<ul style="list-style-type: none"> ▪ 2023 Project Ministry of Economic Development MISE F/310107/01/X56 ARKETIPO - ARTIFICIAL INTELLIGENCE FOR EARLY RISK PREDICTION OF HEART FAILURE BY COMBINING CIRCULATING EPI SIGNATURE TO CLINICAL FEATURES - ▪ 2023 PNRR Project Ministry of University and Research ANTHEM (Advanced Technologies for Human-centred Medicine) ▪ 2023 Project “A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (STUDIO VICTORION-1 PREVENT)". NOVARTIS Protocol CKJX839D12302. EU CT Number 2022-502779-40-00 2020-EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY (COST) EU RTD framework programme, Horizon 2020 - CA19127 - Cognitive decline in Nephro-Neurology: European Cooperative Target • 2019. Funding for PRIN project, from the MIUR (Italian Ministry for University and Research) Call 2017 start from 01/09/2019). Project: “The Incretin Hormones and their analogues as physiological and pharmacological regulators of a complex multi-organ network” (prof. A. Consoli – Gabriele D’Annunzio University Chieti- Pescara). • 2018 -Project: “Innovative Device for Shaping the risk of Diabetes – Acronym IDF SHARID” Coordinator: Technology District Campania Bioscience. Industrial Research and Experimental Development Projects in the 12 Areas of Specialization identified from PNR 2015-2020” (prof. F. Beguinot- University of Naples “Federico II”). • 2018. POR FESR CAMPANIA 2014-2020 Oncology CARE Management. (Acronym OnCARE) CUP B53D18000080007. • 2018. POR CAMPANIA FESR 2014/2020 – ASSE 1 – OO.SS. 1.2.2/1.1.2. Identification, Characterization and mining of colorectal tumorigenesis: cause, prevention & cure (Acronym iCURE) "iCURE" CUP B21C17000030007. • 2014-2017 - “A long term, randomized, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus” HARMONY study GLP116174– GSK. • 2014- 2017. Pfizer/Merck, Mk-8835-003/ B1521022 - Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With A 26-Week Extension to evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of subjects with type 2 diabetes mellitus and inadequate glycemic control despite diet and exercise (PAREXEL number 210225). • 2014-2017 - Pfizer/Merck, Protocol Number MK-8835-004/B1521021- Protocol Title: Randomized, double-blind, placebo-controlled, parallel-group study to assess cardiovascular outcomes following treatment with ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus and established vascular disease - PAREXEL Number: 210224, site 127 . • 2017. AIFA Convention Pharmacovigilance Research Projects 21.03.2016 “Risk of drug and drug-pathology interactions in treatment of heart failure in elderly patients”.

Additional information	<ul style="list-style-type: none"> • 2017 (call 2015) Funding for PRIN project, from the MIUR (Italian Ministry for University and Research) - Molecular, translational and clinical age's aspects related metabolic diseases. National Coordinator: Giuseppe Paolisso. • 2016 Funding from the Italian Ministry for Health. Network Project (NET-2013-02356764). Start 01/08/2016 geriatric outcomes among older type 2 diabetic patients treated with dpp4-inhibitors or glinides (GOOD). • 2015 (Call 2014 start 01/03/2015) Funding from the Campania Region. Implementation of accreditation procedure and correct use of hospital and territorial services of elderly patient of Campania Region. •2011 - FP7 EP7-HEALTH-2011- HEALTH-2011- two stage-SP1: Project n 278803 "A randomized trial to evaluate the effectiveness of a multi-modal intervention in older people with type 2 diabetes on frailty and quality of life: the mid-frail study" Project n 278803 Scientific Coordinator: Dr. Leocadio Rodriguez Manas (Madrid Spain). National Coordinator: Prof. Giuseppe Paolisso. • 2011 Funding from the Italian Ministry for Health - National Center for Disease Prevention and Control (CCM) 2011 "promotion of living styles for preventing disability in elderly".
Bibliometric indices	<p>PubMed publications: 553; Citations (Scopus): 31822; H index (Scopus): 90 Total Impact Factor: >2700 TOP ITALIAN SCIENTISTS (TIS), n• 43 nel 2019; 1% Top scientists PLOS Biology 2020</p>
Main Research Topics	<p>Study of the molecular and metabolic aspects of aging and longevity including the relationships between aging, glucose metabolism and cardiovascular diseases; Definition of the cardiometabolic risk in the elderly patient.; Study of the role of the different genetic polymorphisms in metabolic diseases linked to aging and determinism of longevity.;Study of epigenetic modifications (methylation, miRNA etc, histone modifications) occurring in cardiovascular diseases and ageing; Study of the role of lifestyle in preventing fragility.; Study of glycemic variability and its relation to the development of diabetic.;Cardiovascular complications in adults and the elderly.; Study of the relationship between glycemic variability and cognitive and functional decline.</p>
Relevant publications	<ul style="list-style-type: none"> — Sardu C, Trotta MC, Sasso FC,, Pizzi C, Paolisso G, Marfella R. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. <i>Cardiovasc Diabetol.</i> 2023 Apr 1;22(1):80. doi: 10.1186/s12933-023-01814-7. — Marfella R, Sardu C, D'Onofrio N, C, Del Visco L, Paolisso G. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. <i>BMC Med.</i> 2023 Feb 24;21(1):71. doi: 10.1186/s12916-023-02781-2. — Marfella R, D'Onofrio N,, Paolisso G. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. <i>Metabolism.</i> 2022 Feb;127:154936. — Marfella R, Amarelli C, Cacciatore F, Balestrieri ML, ... C, Paolisso G, Napoli C. Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. <i>J Am Coll Cardiol.</i> 2020 Mar 24;75(11):1249-1262 — Sardu C, Paolisso P, Sacra C, Mauro C, Paolisso G, Marfella R. Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. <i>Diabetes Care.</i> 2019 Oct;42(10):1946-1955.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Naples, 12/06/2023

Giuseppe Paolisso